Catalyst Biosciences Current Ratio 2006-2021 | CBIO

Catalyst Biosciences current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Catalyst Biosciences Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.10B $0.02B 6.22
2021-03-31 $0.12B $0.01B 8.22
2020-12-31 $0.09B $0.02B 5.03
2020-09-30 $0.11B $0.02B 6.42
2020-06-30 $0.12B $0.01B 8.88
2020-03-31 $0.11B $0.01B 9.14
2019-12-31 $0.10B $0.03B 3.32
2019-09-30 $0.09B $0.01B 9.82
2019-06-30 $0.10B $0.01B 15.83
2019-03-31 $0.11B $0.00B 24.94
2018-12-31 $0.12B $0.01B 25.83
2018-09-30 $0.13B $0.00B 40.20
2018-06-30 $0.14B $0.00B 56.98
2018-03-31 $0.15B $0.00B 50.15
2017-12-31 $0.04B $0.01B 4.48
2017-09-30 $0.03B $0.01B 3.58
2017-06-30 $0.04B $0.01B 4.23
2017-03-31 $0.03B $0.02B 1.87
2016-12-31 $0.04B $0.02B 1.71
2016-09-30 $0.05B $0.03B 1.59
2016-06-30 $0.06B $0.03B 1.67
2016-03-31 $0.06B $0.03B 1.82
2015-12-31 $0.07B $0.04B 1.82
2015-09-30 $0.07B $0.04B 1.92
2015-06-30 $0.10B $0.00B 60.98
2015-03-31 $0.11B $0.00B 26.96
2014-12-31 $0.00B $0.00B 0.89
2014-09-30 $0.10B $0.00B 30.82
2014-06-30 $0.10B $0.01B 13.17
2014-03-31 $0.10B $0.01B 9.98
2013-12-31 $0.09B $0.01B 8.53
2013-09-30 $0.10B $0.01B 9.27
2013-06-30 $0.10B $0.01B 11.91
2013-03-31 $0.11B $0.01B 13.33
2012-12-31 $0.13B $0.01B 11.26
2012-09-30 $0.15B $0.01B 15.10
2012-06-30 $0.16B $0.01B 12.17
2012-03-31 $0.18B $0.05B 3.72
2011-12-31 $0.20B $0.08B 2.52
2011-09-30 $0.22B $0.09B 2.32
2011-06-30 $0.24B $0.09B 2.66
2011-03-31 $0.20B $0.09B 2.15
2010-12-31 $0.22B $0.10B 2.21
2010-09-30 $0.23B $0.10B 2.43
2010-06-30 $0.25B $0.10B 2.54
2010-03-31 $0.29B $0.09B 3.38
2009-12-31 $0.31B $0.10B 3.11
2009-09-30 $0.08B $0.01B 5.80
2009-06-30 $0.08B $0.01B 5.96
2009-03-31 $0.09B $0.01B 6.95
2008-12-31 $0.09B $0.01B 6.67
2008-09-30 $0.10B $0.01B 6.93
2008-06-30 $0.11B $0.01B 7.58
2008-03-31 $0.10B $0.01B 7.18
2007-12-31 $0.09B $0.02B 6.08
2007-09-30 $0.09B $0.01B 8.00
2007-06-30 $0.07B $0.01B 7.98
2007-03-31 $0.07B $0.01B 10.60
2006-12-31 $0.08B $0.01B 8.81
2006-09-30 $0.06B $0.01B 8.49
2006-06-30 $0.07B $0.01B 9.77
2006-03-31 $0.03B $0.01B 5.67
2005-12-31 $0.03B $0.01B 4.94
2005-09-30 $0.00B 0.00
2005-06-30 $0.00B 0.00
2005-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.103B $0.021B
Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic which are in clinical different trail. Catalyst Biosciences, Inc., formerly known as Targacept, Inc., is based in South San Francisco, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86